FHL2 and cancer: In complex with FHL2 (four- and one-half LIM domains protein 2), β-catenin, and Lef-1 (lymphoid enhancer-binding factor-1), EpICD has been shown to induce the transcription of specific oncogenes, such as cyclins and c-myc, thereby promoting cancer cell proliferation (63).